neurodegenerative disease

Membraneless droplet like organelles known as condensates are changing the way some scientists approach drug discovery.

Scientists leverage the natural ability of antibodies to cross the blood-brain barrier and target proteins implicated in neurodegenerative disease.

Researchers built a framework to purposefully identify drug candidates for repurposing.

By fusing a brain-targeted antibody with an antibody that protects neurons from degeneration, scientists developed a new class of drugs that can traverse the blood brain barrier, enabling potential new treatments for Parkinson’s disease, Alzheimer’s disease, and depression.